Evidence map›Paper›PMID 40014051›Full record

ArticleDisease models & mechanisms2025

Precise photopharmacological eradication of metastatic tumor cells.

Adam Varady, Sarah Grissenberger, Andrea Wenninger-Weinzierl, Hugo Poplimont, Caterina Sturtzel, Nicole Schmitner, Li Gao, Robin A Kimmel, Martin Distel

Abstract read
In one paragraph

Article in Disease models & mechanisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adam VaradySt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Sarah GrissenbergerSt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Andrea Wenninger-WeinzierlSt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Hugo PoplimontSt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Caterina SturtzelSt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.
Nicole SchmitnerInstitute of Molecular Biology/CMBI, University of Innsbruck, 6020 Innsbruck, Austria.
Li GaoLudwig Maximilian University of Munich, 80539 Munich, Germany.
Robin A KimmelInstitute of Molecular Biology/CMBI, University of Innsbruck, 6020 Innsbruck, Austria.
Martin DistelSt. Anna Children's Cancer Research Institute, 1090 Vienna, Austria.ORCID 0000-0001-5942-0817

Funding

Alex's Lemonade Stand Foundation for Childhood Cancer 20-17258Austrian Science Fund P30038-BBLÖsterreichische Forschungsförderungsgesellschaft 7940628Österreichischen Akademie der WissenschaftenSt. Anna Children's Cancer Research Institute
6 · The paper itself

Abstract

Owing to their high efficacy, antimitotic chemotherapeutics are the mainstay for most cancer treatments. However, these drugs do not discriminate between tumor and healthy cells, thus show dose-limiting toxicity and severe adverse effects. To improve treatments, rendering chemotherapeutics tumor-cell specific is highly desirable. Although various strategies, such as targeted antibody-drug conjugates, aim to achieve this goal, the identification of a tumor-specific 'Achilles' heel' remains a challenge. Here, we followed an alternative approach, which does not rely on tumor-specific characteristics, but rather uses spatially confined illumination of the light-activatable microtubule inhibitor SBTubA4P to target its cytotoxic activity to tumor cells. We demonstrate that localized illumination of SBTubA4P allows for precise eradication of disseminated sarcoma cells in zebrafish xenografts without inducing systemic toxicity. In addition to the already-described light-dependent inhibition of microtubule dynamics by SBTubA4P, our data indicate that this molecule creates reactive oxygen species upon UV illumination, which significantly increases its cytotoxic effects. SBTubA4P is a valuable addition to the precision oncology toolbox, and zebrafish xenografts constitute a well-suited model to investigate photoactivatable compounds in vivo.

Indexed as

MicrotubulesPhotochemotherapyAnimalsCell Line, TumorHumansNeoplasm MetastasisReactive Oxygen SpeciesSarcomaUltraviolet RaysXenograft Model Antitumor AssaysZebrafishReactive Oxygen SpeciesMicrotubulesPhotodynamic therapyPhotopharmacologyROSSarcomaZebrafish xenografts

Identifiers

PMID40014051
PMCPMC11892682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.